Skip to content

Biomarkers For Early Diagnosis Of Pre Diabetes In pancreatic Disease

Plasma Metabolomic Profiling To Identify Metabolic Biomarkers For Early Detection Of Prediabetes Associated With Pancreatogenic Diabetes (Type3cDM) In Chronic Pancreatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/02/023208
Enrollment
520
Registered
2020-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K861- Other chronic pancreatitis

Interventions

None listed

Sponsors

Science and Engineering Research Board
Lead Sponsor
Asian Healthcare Foundation
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: The diagnosis of chronic pancreatitis is based on two or more of the following findings: a.Patients who have had abdominal pain of > 6 months duration without diabetes b.Patients with history of recurrent acute pancreatitis with > 3 episodes of pain associated with imaging diagnostic of acute pancreatitis and/or elevated serum amylase or lipase 3 times normal. c.CP diagnosed by Pancreas calcifications on CT scan, or abnormal ERCP; ductal or parenchymal abnormalities on Endoscopic ultrasonography, d.Histopathologic confirmed diagnosis of chronic pancreatitis Ability to give informed consent

Exclusion criteria

Exclusion criteria: 1.Age less than 18 or more than 60 years 2.CP patients with diabetes 3.CP patients with other comorbidities and Patients with grossly atrophic pancreas on imaging 4.CP patients with malignancy 5.Pregnant or lactating women 6.Inability to give informed consent.

Design outcomes

Primary

MeasureTime frame
The proposed study would result in identification of metabolic signatures for early detection of prediabetes in chronic pancreatitis.Timepoint: Metabolic signatures will be assessed at baseline

Secondary

MeasureTime frame
Aberrant metabolomic pathways may aide in development of targeted therapy for management of diabetes in chronic pancreatitisTimepoint: 3 Years

Countries

India

Contacts

Public ContactMITNALA SASIKALA

Asian Healthcare Foundation

aigres.mit@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026